Trial Profile
An International, Multicentre, Observational, Prospective, Longitudinal Cohort Study to Assess the Impact of Integrated Upper Limb Spasticity Management Including the Use of BoNT-A- Injections on Patient-centred Goal Attainment in Real Life Practice - ULIS III
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jun 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Therapeutic Use
- Acronyms ULIS III
- Sponsors Ipsen
- 18 May 2022 Results presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology
- 15 Jan 2021 According to an Ipsen media release, data will be presented at the TOXINS 2021 conference.